fbpx
Connect with us

health and wellness

New Report Highlights Alarming Increase in Prostate Cancer and Advanced Stage Diagnoses

Published

on

Findings heighten concern for Black men, who are at the highest risk for
diagnoses and deaths

WASHINGTON /PRNewswire/ — Prostate cancer continues to be one of the most common cancers among men nationwide, showing a 3% increase in incidence per year and a 5% increase in advanced-stage diagnoses per year since 2014, a new report shows. The report also shows that Black men continue to face disproportionate diagnoses and mortality rates, with the incidence of prostate cancer being more than 70% higher in Black men compared to white men.

“An aging population, a pandemic, and a refusal by the United States Preventive Services Task Force (USPSTF), a Congressionally authorized group of volunteer prevention experts, to recognize the benefits of screening has created the perfect storm for increasing prostate cancer deaths and cases,” said Jamie Bearse, ZERO’s President & CEO. “This perfect storm is affecting Black patients much harder than anyone else. The way forward in fighting this appalling trend is building a diverse nationwide community of patients, caregivers, doctors, lawmakers, and partners that are equipped to advocate for better access to testing and quality care and improve education and screening outreach, especially to high-risk groups.”

Prostate cancer remains the most commonly diagnosed cancer in men (aside from skin cancers) and second leading cause of cancer death in men. According to the report, the 5-year survival rate for men has decreased from 98% in 2022 to 97%. 

“Prostate cancer awareness is a significant issue for me because if I had known that military service or family history had increased my chances of developing prostate cancer, I might have been diagnosed earlier,” said Darrell Wilson, an advanced prostate cancer patient.

The report showed that prostate cancer disparities between Black and white men are at their highest in over a decade. According to new data from 2022, prostate cancer is reported to consist of 37% of cancers diagnosed among Black men, with 41,600 new cases expected this year.

“Black men are nearly twice as likely to be diagnosed with and more than twice as likely to die from prostate cancer than white men. The sorting of money, knowledge, power, and beneficial social connections by race contribute to sustaining these differences over time,” said Dr. Reggie Tucker-Seeley, ZERO’s Vice President of Health Equity. “We cannot end prostate cancer without addressing the root causes of race and place-based disparities in prostate cancer.”

As the nation’s leading nonprofit in the fight against prostate cancer, ZERO recognizes that only when we can solve the growing health equity divide for those with the highest risk can we end this disease together. ZERO is addressing the health equity divide with our Health Equity Task Force and the Black Men’s Prostate Cancer Initiative. ZERO also partnered with the Prostate Cancer Foundation to create the Young Investigator Award for innovative research into the causes of racial disparities in prostate cancer and potential strategies to reduce them.

In November, ZERO led a White House discussion on prostate cancer as a part of the Biden administration’s Cancer Moonshot Initiative. HHS Secretary Xavier Becerra was part of the roundtable, which focused on increasing prostate cancer awareness and access to screening among men of color. Representatives from the American Cancer Society, Prostate Cancer Foundation, 100 Black Men of America, and Prostate Health Education Network participated in the discussion.

ZERO is combating the rising statistics by making screenings affordable and accessible nationwide. Last year, ZERO led advocacy efforts in Illinois to pass legislation to make prostate cancer screening available without co-pays or other cost-sharing, which will go into effect in 2024. Illinois will follow in the footsteps of New York, which in January of 2019 became the first state in the country to pass a law that supports full insurance coverage of the PSA (prostate-specific antigen) blood test, as well as Maryland and Rhode Island, all of which have eliminated co-pays or cost-sharing fees for prostate cancer screening.

To join the fight against prostate cancer, sign up for the 2023 ZERO Prostate Cancer Summit, the largest annual gathering of the prostate cancer community. For more information, support, and resources, visit zerocancer.org.

About ZERO – The End of Prostate Cancer:

ZERO — The End of Prostate Cancer is the leading national nonprofit with the mission to end prostate cancer and help all who are impacted. ZERO advances research, provides support, and creates solutions to achieve health equity to meet the most critical needs of our community. From early detection to survivorship, ZERO is the premier resource for prostate cancer patients and their families to access comprehensive support, make meaningful connections, and take action to save lives.

SOURCE ZERO – The End of Prostate Cancer

health and wellness

The Philadelphia Phillies Join Forces with NPCF in the Fight Against Childhood Cancer

Philly Phillies & NPCF join forces to fight childhood cancer, raising awareness and funds through “Cut and Color Funds the Cure” event. #TogetherAgainstCancer

Published

on

Bay Care Ballpark for the "Cut and Color Funds the Cure" event, showing their support for childhood cancer awareness and the National Pediatric Cancer Foundation.
Fighting Childhood Cancer: Larry Bowa at the Phillies Cut and Color Funds the Cure for the National Pediatric Cancer Foundation

It is with great pride and admiration that we share the inspiring collaboration between the Philadelphia Phillies and the National Pediatric Cancer Foundation (NPCF). On Friday, March 22, the Phillies organized a remarkable event called “Cut and Color Funds the Cure” at Bay Care Ballpark. This event brought players, staff members, and supporters together to either cut or color their hair red or orange – the official colors of both the Phillies and NPCF. The primary goal of this program was to raise awareness and funding for pediatric cancer research, with the aim of finding a cure for the 43 children diagnosed with cancer every day.

The “Cut and Color Funds the Cure” event showcased the Philadelphia Phillies’ unwavering commitment to making a positive difference in the lives of children battling cancer. By embracing the red and orange hair colors associated with the team and NPCF, players and staff members symbolically demonstrated their solidarity and dedication to the cause. This vibrant display of unity helped generate widespread awareness and captivated the attention of both avid baseball fans and the general public.

  1. In joining forces with NPCF, the Phillies recognized the power of their platform to bring attention to pediatric cancer. By leveraging their influence and engaging in events like “Cut and Color Funds the Cure,” they are raising awareness about this harrowing disease and its impact on children and their families. The collective efforts of the Phillies and the NPCF not only inform the public but also foster a sense of empathy and compassion, inspiring others to join the fight against childhood cancer.

  2. The National Pediatric Cancer Foundation is renowned for its dedication to funding innovative research aimed at eliminating childhood cancer. By partnering with leading hospitals and research institutions nationwide, the foundation strives to find less toxic and more targeted treatment options. The collaboration with the Philadelphia Phillies further bolsters these efforts by providing resources and support to enable groundbreaking advancements in pediatric cancer research.

  3. The Philadelphia Phillies firmly believe in the power of sports to make a positive impact on their community. Through the “Cut and Color Funds the Cure” event, they actively engaged their fans and supporters, encouraging them to contribute to the cause. By creating an inclusive and participatory environment, the Phillies fostered a sense of community and amplified the collective strength of their loyal fanbase.


The partnership between the Philadelphia Phillies and the National Pediatric Cancer Foundation exemplifies the extraordinary potential of collaboration and collective action. By joining forces, the team and the foundation are driving forward the fight against childhood cancer, inspiring hope and uniting people from all walks of life. Through events like “Cut and Color Funds the Cure,” the Phillies demonstrate their unwavering commitment to improving the lives of children battling this devastating disease. Together, we can create a better tomorrow for these young heroes and pave the way for a future without pediatric cancer.

About National Pediatric Cancer Foundation
The National Pediatric Cancer Foundation (founded in 1991) is a national nonprofit organization dedicated to funding research to eliminate childhood cancer. We govern a unique, collaborative research consortium (called the Sunshine Project) consisting of physicians and scientists from over thirty of the top hospitals in the nation. We collaborate to idealize and aggregate the best scientific ideas and fund innovative research. The NPCF has received a perfect 100% score for financial health and transparency and is recognized as the top-rated cancer charity in the U.S. by Charity Navigator. For more information, visit NationalPCF.org or connect via FacebookTwitter or Instagram.

SOURCE National Pediatric Cancer Foundation

Want more stories 👋
"Your morning jolt of Inspiring & Interesting Stories!"

Sign up to receive awesome articles directly to your inbox.

We don’t spam! Read our privacy policy for more info.

Continue Reading

FDA CDC News

FDA Approval of Nonsteroidal Treatment for Duchenne Muscular Dystrophy

Breaking news! FDA approves Duvyzat for Duchenne Muscular Dystrophy, a nonsteroidal treatment providing hope for patients and families. #DMD #FDAApproval

Published

on

Breaking news in the medical world! The U.S. Food and Drug Administration has just approved Duvyzat (givinostat), an oral medication for the treatment of Duchenne Muscular Dystrophy (DMD) in patients six years of age and older. Duvyzat is making history as the first nonsteroidal drug approved to treat patients with all genetic variants of DMD. This is a significant milestone in the treatment of this devastating disease.

DMD, being the most common childhood form of muscular dystrophy, primarily affects males. It is a neurological disorder that leads to progressive muscle weakness due to a lack of dystrophin, a muscle protein. Over time, the muscles deteriorate, causing difficulties with walking, muscle strength, and eventually leading to breathing problems and early death. However, with advancements in treatment, the life expectancy for individuals with DMD has been steadily increasing, with some patients surviving beyond 30 years.

Duvyzat is a histone deacetylase (HDAC) inhibitor that targets pathogenic processes to reduce inflammation and loss of muscle in patients with DMD. Its efficacy for the treatment of DMD was evaluated in an 18-month phase 3 study involving a randomized, double-blind, placebo-controlled trial. The primary endpoint of the study was the change in muscle function, measured by the time it took patients to climb four stairs. Patients treated with Duvyzat showed a statistically significant reduction in the decline of muscle function compared to placebo.

Another measure of efficacy was the change in physical function assessed by the North Star Ambulatory Assessment (NSAA), a scale commonly used to rate motor function in boys with DMD who can still walk. Patients treated with Duvyzat experienced less worsening in their NSAA scores after 18 months, compared to those on placebo.

Like any medication, Duvyzat does come with some potential side effects. The most common ones reported were diarrhea, abdominal pain, a decrease in platelets, nausea/vomiting, an increase in triglycerides, and fever. It’s important for healthcare providers to evaluate a patient’s platelet counts and triglyceride levels before prescribing Duvyzat. Patients with low platelet counts should not take the drug. Monitoring of platelet counts and triglycerides throughout treatment will help determine if any dosage adjustments are needed.

Healthcare professionals should also be aware that Duvyzat may cause QTc prolongation, which can increase the risk of irregular heartbeats. It’s crucial for patients taking other medications known to cause QTc prolongation or with certain types of heart disease to avoid taking Duvyzat.

The recommended dosage of Duvyzat is determined by the patient’s body weight, and it should be taken orally twice daily with food.

The approval of Duvyzat was granted to Italfarmaco S.p.A., and it received priority review, fast-track designation, as well as orphan drug and rare pediatric disease designations from the FDA. This demonstrates the agency’s commitment to advancing the development of new therapies for DMD and its recognition of the urgent need for effective treatments.

This milestone approval represents hope and progress for individuals and families affected by DMD. It provides another treatment option to help reduce the burden of this progressive and debilitating disease, regardless of the specific genetic mutation. With continued advancements in medical research and the dedication of organizations like the FDA, we are moving closer to a future where individuals with DMD can lead healthier lives.

As always, it’s important to consult with healthcare professionals for more information and guidance regarding Duvyzat and its suitability for individual cases. Let’s celebrate this achievement in medical science and look forward to more groundbreaking developments in the treatment of Duchenne Muscular Dystrophy.

Source: FDA

Related Information

  • Duchenne muscular dystrophy – About the Disease – Genetic and Rare Diseases Information Center
  • The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

https://stmdailynews.com/category/lifestyle/

Continue Reading

fitness

Milk Hosting EVERY WOMAN’S MARATHON – The Only U.S. Marathon Designed for Women, by Women

Published

on

SAVANNAH, Ga. /PRNewswire/ — Acknowledging the historically intimidating and male-centric nature of marathons, Milk, the original performance beverage, proudly announces Every Woman’s Marathon, the only U.S. marathon designed by and for women. Scheduled for November 16, 2024, in Savannah, Georgia, this monumental event marks a new chapter in Milk’s commitment to supporting women – creating not only a race, but a movement.

Amanda Gorman’s Inspirational Mantra to Announce Milk’s Every Woman’s Marathon. Join Team Milk in Savannah, Georgia on November 16, 2024, for the only US Marathon for Women by Women. Milk’s unique nutrient package offers high-quality protein, hydration, and electrolytes, providing critical nutrition for runners’ fuel and recovery.

Most women runners feel endurance races cater to men, and nearly 90% want a more inclusive race experience that celebrates all athletic abilities, ages, and body types1. As a solution to this gap in marathon racing, Milk designed the Every Woman’s Marathon to be inclusive, beginner-friendly, and attuned to the unique needs of women at every stage of their marathon journey.

Every Woman’s Marathon is not just about crossing the finish line; it’s about celebrating female strength and empowering every woman’s journey through the transformative power of community. Understanding that every woman has their own reason for running, Milk tapped acclaimed poet Amanda Gorman to create an inspirational mantra designed as a call to action for all women to join the movement. Narrated and penned by Gorman, the mantra highlights women of all sizes, backgrounds, races, and abilities, and why they run.

To help conceptualize Every Woman’s Marathon, Milk enlisted an advisory board comprised of five accomplished female runners, first female marathon finisher Kathrine Switzer, para-triathlon champion Danielle McLaughlin, Olympic Medalist Deena Kastor, trailblazer Alison Mariella Désir and Two-time Olympian and 2018 Boston Marathon Champion Des Linden, who collaborated to create an inclusive experience for women from registration to the finish line. Transcending the traditional race format, this marathon promises participants a comprehensive wellness weekend in the picturesque city of Savannah. The two-day event will include enriching activities such as cooking and yoga classes, live performances, and insightful panels. With thoughtful programming that prioritizes women and families, the event will also feature designated areas for nursing, pumping, play zones, and more, ensuring a welcoming and inclusive experience for all participants.

Beyond providing specialized training advice and nutrition plans tailored for women, backed by the expertise of the advisory board, Milk is further demonstrating its commitment to social impact by donating up to $1 million to charity organizations in support of women and girls across the US. Milk is proud to announce a donation of $100,000 to each of the five Every Woman’s Marathon charity partners, 261 FearlessBlack Girls RUN!Girls on the RunGirl Scouts of Historic Georgia, and St. Jude Children’s Research Hospital®. Milk is also helping runners amplify the impact by matching Every Woman’s Marathon registration costs in donations to the charity partners, up to $100,000 each.

“Milk has a centuries-old legacy of fueling performance and aiding recovery and can help runners go the distance with its unique nutritional package,” says MilkPEP CEO Yin Woon Rani. “We proudly recognize and champion the unique needs of women, and this marathon, crafted for and by women, will redefine the traditional marathon experience. Together, let’s make Every Woman’s Marathon not just a race but a celebration of women’s empowerment, resilience, and the unstoppable spirit of every woman.”

“Words and representation have the power to inspire change and unite,” says poet Amanda Gorman. “I am proud to partner with Milk on this mantra that speaks to the strength and resilience of women, and I encourage all women to take on this 26.2-mile challenge together.”

In addition to providing women with support, inspiration, and community, Milk also provides the essential nutrition runners seek. Milk’s unique nutrient package offers high-quality protein, hydration, and electrolytes, providing critical nutrition for runners’ fuel and recovery.

Starting January 23, 2024, women of all backgrounds and abilities can sign up for Every Woman’s Marathon to join the most inspiring female tribute of the year at EveryWomansMarathon.com. Signing up costs $65, with current Team Milk members enjoying an even further reduced price. Learn more at EveryWomansMarathon.com or @EveryWomansMarathon across social media.

About the Milk Processor Education Program

The Milk Processor Education Program (MilkPEP), Washington, D.C., is funded by the nation’s milk companies and is dedicated to educating consumers and increasing the consumption of fluid milk. For more information, visit MilkPEP.org.

1Interviews of 1205 runners (880 female, 325 male) in September 2023 on behalf of MilkPEP.

SOURCE MilkPEP

Continue Reading

Trending